In 2024, OpenAI CEO Sam Altman famously predicted that a single entrepreneur, leveraging the transformative power of artificial intelligence, could build a business worth over one billion dollars. This audacious forecast seemed to find its poster child in Matthew Gallagher, the Los Angeles-based entrepreneur behind the telehealth startup MEDVi. On April 2, 2026, The New York Times published a glowing profile, presenting MEDVi as a prime example of Altman’s vision brought to life. The article highlighted Gallagher’s claim of an AI-powered path to a projected $1.8 billion in sales by 2026, achieved with a remarkably lean operation consisting of just two full-time employees—Gallagher himself and his brother Elliot—supplemented by contract engineers, account managers, and outside agencies. The Times affirmed that it had been granted access to MEDVi’s financials, purportedly verifying the impressive revenue and profit figures.
Gallagher detailed to the Times how he harnessed a suite of AI services, including ChatGPT, Claude, Grok, MidJourney, and Runway, to construct the company’s operational framework. He entrusted the crucial aspects of medical care, pharmacy operations, shipping, and regulatory compliance to established telehealth-in-a-box platforms, specifically CareValidate and OpenLoop Health. This model, often referred to as white-label telemedicine, allows companies like MEDVi to focus on marketing and customer acquisition while outsourcing the medical and logistical complexities. On LinkedIn, Gallagher had at one point boldly declared MEDVi "the fastest growing company in history," a claim he has since retracted from his public profile. The company’s current homepage prominently states "500,000+ MEDVi patients," promising "unlimited 24/7 support" and "doctor-led plans & coaching."
Regulatory Warnings Cast a Shadow
However, the narrative of MEDVi’s meteoric rise began to unravel almost immediately, revealing a complex web of regulatory challenges and ethical concerns that pre-dated the New York Times spotlight. Just six weeks before the high-profile Times article, on February 20, 2026, the U.S. Food and Drug Administration (FDA) issued a direct warning letter to MEDVi, LLC, citing significant misbranding of the compounded drugs that were generating its substantial revenue.
The FDA’s letter, addressed to "MEDVi, LLC dba MEDVi" at its registered address in Newark, Delaware, and sent to a MEDVi-branded email address, specifically flagged several misleading claims on the company’s website, medvi.io. Among these were assertions like "Same active ingredient as Wegovy® and Ozempic®" for semaglutide products and "Same active ingredient as Mounjaro® and Zepbound®" for tirzepatide products. The FDA asserted that these statements falsely implied agency approval or evaluation, which is prohibited for compounded medications. Furthermore, the agency warned that the site misleadingly suggested MEDVi was the actual compounder of these drugs, rather than a tele-health intermediary. The FDA underscored the gravity of these violations, cautioning that failure to rectify them could lead to enforcement actions, including product seizure or injunctions. Critically, the warning letter concluded with a statement that the cited violations were not exhaustive, implying the potential for further regulatory scrutiny.
In response to the FDA’s public warning, MEDVi issued a statement on April 8, claiming that the FDA-cited website, medvi.io, belonged to an affiliate marketing agency and that MEDVi itself had "never received a letter from the FDA." This assertion, however, stood in direct contradiction to the official FDA document, which clearly identified MEDVi, LLC as the recipient and directly referenced the MEDVi-branded claims found on medvi.io.
The Pervasive Issue of Deceptive AI Advertising
Beyond the misbranding issues, independent investigations quickly unearthed a pattern of deceptive marketing practices, heavily reliant on artificial intelligence, that extended beyond the FDA’s initial findings. A review conducted on April 3 by Drug Discovery & Development of MEDVi’s website, Facebook advertising, and public records revealed numerous apparent AI-generated personas, some even presented with medical titles. A search of Meta’s Ad Library for "medvi" yielded over 5,000 active ads, many operating under what appeared to be fabricated physician personas.
For instance, a Facebook page for "Dr. Robert Whitworth," which sponsored ads for MEDVi’s QUAD erectile dysfunction product, was incongruously categorized as an "Entertainment website" and listed a non-existent address in Cameron, Montana. Other ads featured names like "Professor Albust Dongledore" and "Dr. Richard Hörzgock," utilizing AI-generated video testimonials and recycling identical scripts across multiple seemingly distinct, yet fabricated, personas. In some cases, a doctor’s headshot would be displayed on the page, while the accompanying ad featured an entirely unrelated individual delivering a patient testimonial. A follow-up review on April 6 observed that many of these questionable doctor personas had been removed from the site, suggesting a swift, albeit reactive, cleanup effort.
Further corroboration came from a Business Insider investigation published on the same day, which meticulously scrutinized the historical use of apparent AI-generated doctor profiles in Meta ads for MEDVi, many linked to its extensive affiliate network. Matthew Gallagher admitted to Business Insider that "maybe 30%" of MEDVi’s advertising was conducted through affiliates. Business Insider identified profiles such as "Dr. Matthew Anderson MD," linked to an Angolan phone number and previously associated with a gospel musician, and "Dr. Spencer Langford MD," tied to a clothing store in the Republic of Congo. Other profiles exhibited tell-tale signs of AI generation, including garbled text and Gemini watermarks. Following Business Insider‘s inquiries to Gallagher, the number of active Medvi-related ads on Meta platforms reportedly dropped significantly, from over 5,000 to approximately 2,800.
Gallagher, in his defense to Business Insider, stated, "In line with the FTC, we have a clear policy of providing disclosure on any actor or AI portrayal of a doctor or not using them at all. If we find an affiliate doing this we work to take these ads down." However, this statement appeared inconsistent with his public posture on social media. Nancy Glick, director of food, nutrition, and obesity at the National Consumers League, voiced strong criticism of MEDVi, reiterating her organization’s long-standing warnings against the use of unregulated GLP-1 products.
MEDVi’s own website includes a subtle disclaimer at the bottom, acknowledging, "Individuals appearing in advertisements may be actors or AI portraying doctors and are not licensed medical professionals." This fine print, however, does little to address the pervasive nature of the deceptive advertising tactics employed, especially through its vast network of affiliates.
A History of Digital Deception
The use of AI and deceptive imagery was not a new development for MEDVi. As early as May 2025, the technology news site Futurism had documented similar questionable practices on MEDVi’s website. Futurism‘s investigation revealed AI-generated patient photos, deepfaked before-and-after weight loss images (traced to photos that had circulated online for years with faces swapped by AI), and AI-generated Ozempic box imagery containing clear errors. Adding to the facade, logos from The New York Times, Bloomberg, and Forbes were displayed, implying editorial coverage that, at that point, did not exist. When Futurism contacted doctors listed on MEDVi’s site, at least one, osteopathic practitioner Tzvi Doron, explicitly stated he had no association with the company and requested his removal. In the subsequent Times profile, Gallagher implicitly acknowledged these earlier deceptive practices, admitting that MEDVi’s initial site featured AI-generated photos and before-and-after weight loss images using faces swapped from other online sources.
Further concerns arose regarding the actual medical professionals affiliated with MEDVi. The company’s site previously listed two physicians, Dr. Ana Lisa Carr and Dr. Kelly Tenbrink, both associated with Ringside Health, a concierge practice in Wellington, Florida, serving the equestrian community. MEDVi’s site, however, did not explicitly identify their affiliation with Ringside Health. While Dr. Tenbrink was listed as certified by the American Board of Emergency Medicine on an ABEM credential page, his Florida Department of Health practitioner profile reportedly listed no specialty board certifications recognized by the Florida board. Dr. Carr was listed under St. George’s University School of Medicine, her medical school. Following inquiries from Drug Discovery & Development to both physicians and after the initial publication of the story, MEDVi entirely removed Dr. Ana Lisa Carr and Dr. Kelly Tenbrink from its website on April 10, further highlighting the transient and opaque nature of its physician network.
The Compounding Conundrum: Navigating GLP-1 Regulations
MEDVi’s business model hinges on navigating a complex and constantly evolving regulatory landscape surrounding compounded GLP-1 drugs. Federal law generally prohibits compounders from creating copies of FDA-approved drugs. However, Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding under specific circumstances, notably during drug shortages. The immense popularity of GLP-1 agonists like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) for weight loss and diabetes management led to widespread shortages.
This shortage initially opened a window for compounding pharmacies to produce generic versions. However, the FDA declared the tirzepatide injection shortage resolved on December 19, 2024, followed by the resolution of the semaglutide injection shortage on February 21, 2025. With these official resolutions, the regulatory justification for compounding "copies" significantly diminished.
In response, many sellers, including those potentially supplying MEDVi, pivoted to offering "personalized" formulations, often adding ingredients like vitamin B-12 to the GLP-1 compounds. They argue that these additions render the product not "essentially a copy" of the FDA-approved drugs. However, on April 1, 2026, the FDA clarified its policies, stating that a compounded product combining semaglutide with another active ingredient such as vitamin B-12 may still be considered "essentially a copy" unless a prescriber documents a patient-specific "significant difference" that justifies the compounded formulation. Adding to the caution, in March 2026, Eli Lilly, the manufacturer of Mounjaro and Zepbound, issued an open letter warning against the practice of compounding tirzepatide with vitamin B-12, citing safety and efficacy concerns. This tightening regulatory environment poses a significant challenge to companies like MEDVi relying on such formulations.
Legal Challenges and Patient Safety Concerns
The controversies surrounding MEDVi extend into the legal arena, with the company and its partners facing multiple lawsuits and allegations that raise serious patient safety concerns.
MEDVi reported having 250,000 customers by the end of 2025, with Gallagher describing the growth as "insane" to the Times. This figure has since escalated, with the current MEDVi homepage boasting "500,000+ MEDVi patients." The "doctor-led plans & coaching" promised on the site are facilitated through clinicians provided by OpenLoop Health, a Des Moines, Iowa-based telehealth infrastructure company.
OpenLoop Health itself recently disclosed a significant cyber breach. On January 7, 2026, a threat actor breached OpenLoop’s systems, claiming to have exfiltrated records from approximately 1.6 million patients, including sensitive data such as names, contact information, dates of birth, and medical information. OpenLoop notified the Texas Attorney General in March 2026, confirming at least 68,160 affected individuals in that state alone. This data breach has since led to multiple class-action lawsuits against OpenLoop, highlighting potential vulnerabilities in the broader telehealth ecosystem that MEDVi relies upon.
Furthermore, in November 2025, a North Carolina consumer filed a class-action complaint in the U.S. District Court for the District of Delaware against OpenLoop Health and compounding pharmacy Triad Rx. This lawsuit, first disclosed by Fierce Healthcare, levels a damning accusation: that the firms manufactured and sold what the complaint characterizes as "modern-day snake oil"—compounded oral tirzepatide tablets with "no demonstrated mechanism of absorption or efficacy." While MEDVi is not explicitly named as a defendant, the complaint alleges that the plaintiff purchased the pills through MEDVi, describing it as one of dozens of consumer-facing telehealth storefronts operating within a network managed by OpenLoop.
The scientific basis for this serious allegation is rooted in the molecular properties of tirzepatide, a large peptide molecule that is typically destroyed by digestive enzymes before it can reach the bloodstream. The only FDA-approved oral GLP-1, Rybelsus (oral semaglutide), requires a specialized absorption enhancer called SNAC to achieve a bioavailability of only about 1%, and even then, it must be taken under tightly controlled conditions (e.g., on an empty stomach with a small amount of water). The lawsuit posits that oral tirzepatide compounds, lacking such absorption enhancers, are inherently ineffective. The complaint brings claims under the Racketeer Influenced and Corrupt Organizations Act (RICO Act), state consumer protection statutes, and common law fraud, suggesting a pattern of organized fraudulent activity. It further alleges that MEDVi was one of at least a dozen nearly identical telehealth storefronts, each with a designated OpenLoop patient waiting room, all marketing the same potentially ineffective product through a shared backend infrastructure. Three doctors, including Dr. David Mansour (who appeared in a January 2026 MEDVi press release but is no longer listed on the site) and the previously mentioned Drs. Carr and Tenbrink, were cited by name in the complaint, which asserts that their presentation as "incredible doctors we’ve partnered with" was integral to the marketing scheme.
Beyond the GLP-1 specific allegations, MEDVi has faced other legal skirmishes. The company was served in Siuksta v. MEDVi, LLC, a federal Telephone Consumer Protection Act lawsuit filed in May 2025, but failed to appear, leading to a default notation by the court before the case was voluntarily dismissed. Separately, James v. Medvi LLC, No. 8:26-cv-00641, was filed in the Central District of California on March 20, 2026. This class-action case accuses MEDVi of benefiting from affiliate spam, citing an email with the subject line "This might be the easiest way to start Ozempic" sent from a nonsensical .us email address, which routed to a MEDVi landing page with tracking parameters. Filed under California’s anti-spam law, the suit alleges statutory damages of $1,000 per violating email, with the class potentially numbering at least 100,000 individuals.
Leadership’s Response and Social Media Defenses
Following the decidedly mixed feedback to The New York Times profile, Matthew Gallagher took to social media to defend his company, often with a combative tone. In one deleted X (formerly Twitter) post, he mocked detractors as having low testosterone, labeling them the "Karens of the internet." In another exchange, he directly challenged Shutterstock founder Jon Oringer, who had sarcastically proposed a "fake-doctor affiliate-as-a-service platform." Gallagher equated MEDVi’s use of AI-generated physician personas with the standard practice of using medical stock art in advertising, writing, "The guy who SELLS images of doctors to marketers pretends not to understand marketing. The irony is beautiful," and buttressing his point with a screenshot of a generic stock-style doctor image.
This aggressive defense, particularly his open acknowledgment and justification of AI-generated imagery, stands in stark contrast to MEDVi’s official April 8 statement, which claimed the company had only "recently become aware" of ads featuring "potentially AI-generated medical practitioners." By April 3, Gallagher was already publicly mocking critics and equating the fake-doctor imagery with ordinary stock-art marketing, suggesting a level of awareness and acceptance far beyond a "recent" discovery.
On April 3, 2026, Gallagher posted a longer defense of the white-label telemedicine model, asserting its societal benefits: "Watching in realtime as people learn about white label, drop shipping, and affiliate marketing is like seeing cavemen ‘fire bad’. White label telemedicine is a huge benefit with a net positive for humanity. It has been the driving force behind big pharma lowering prices and making healthcare accessible to everyone from home. Low energy people think offering life-changing weight loss medication, prescribed by a doctor, is a trendy ‘pill mill’. Wait til you see what’s possible with longevity services and peptides. I’m bullish on humanity. If you are too, I’ll help you build."
On LinkedIn, reactions to Gallagher’s posts were divided. Some lauded his AI-first execution and expressed support for his philanthropic goals. Others, however, questioned the reported numbers, with one SEO professional noting that MEDVi’s reported website traffic appeared too low to credibly support the claimed user base and revenue figures. A digital health founder remarked, "Something doesn’t add up," while an accountant suggested a public audit by a reputable firm. A viral YouTube video titled "billion dollar ai company was built on lies," which garnered over a million views within three days, was linked by one user, while a few self-identified customers posted direct complaints about their experiences.
Broader Implications: Trust, Technology, and Regulation
The MEDVi saga raises profound questions about the intersection of rapidly advancing AI technology, the burgeoning telehealth industry, and critical issues of consumer protection and public trust in healthcare.
Firstly, it highlights the significant challenges in regulating AI-generated content, especially in sensitive sectors like medicine. The ease with which AI can create convincing, yet entirely fabricated, personas and testimonials poses a formidable hurdle for regulatory bodies like the FDA and FTC, whose frameworks were largely established in a pre-AI era. The case underscores the need for clearer guidelines and more robust enforcement mechanisms to prevent the deceptive use of AI in health advertising.
Secondly, the reliance on third-party telehealth platforms and compounding pharmacies, while offering scalability, introduces layers of complexity and potential vulnerability. The OpenLoop Health data breach and the "snake oil" allegations against Triad Rx, even if MEDVi is not directly named in all lawsuits, demonstrate the systemic risks inherent in this fragmented model. When a patient interacts with a storefront like MEDVi, the true responsibility and accountability for medical care, product efficacy, and data security can become blurred, complicating efforts to ensure patient safety and legal recourse.
Thirdly, the story serves as a cautionary tale for both investors and the media. The initial uncritical acceptance of MEDVi’s claims, particularly by a prestigious outlet like The New York Times, underscores the allure of "AI success stories" and the pressure to find compelling narratives in a rapidly evolving tech landscape. It highlights the crucial need for rigorous due diligence and skeptical inquiry, especially when groundbreaking technological claims intersect with heavily regulated and public-facing industries like healthcare.
Finally, the incident reinforces the importance of consumer vigilance. The National Consumers League’s repeated warnings about unregulated GLP-1 products and the bipartisan coalition of attorneys general urging Meta to crack down on misleading AI-fueled weight-loss ads underscore a growing awareness of these threats. As AI becomes more sophisticated, the onus on consumers to critically evaluate health claims, verify medical professionals, and understand the regulatory status of their medications will only increase.
Drug Discovery & Development reached out to MEDVi, Matthew Gallagher, OpenLoop Health, Dr. Kelly Tenbrink, and Dr. Ana Lisa Carr for comment but did not immediately receive a response. Nicholas Chimicles, lead counsel for the plaintiffs in one of the class-action lawsuits, declined to comment further on the litigation but confirmed awareness of The New York Times profile of MEDVi. The unfolding narrative of MEDVi stands as a stark reminder that while AI offers immense potential for innovation, it also carries significant risks that demand robust ethical considerations, stringent regulatory oversight, and unwavering commitment to transparency and patient well-being.
Leave a Reply